RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
WuXi AppTec announced a $910 million IPO on the Shanghai exchange for the company’s core small-molecule CRO business. China regulators approved WuXi’s prospectus in a short seven weeks, indicating that they are very eager to list the company, China’s largest CRO, on a domestic exchange. Two years ago, WuXi AppTec de-listed from the New York Exchange in a $3.3 billion privatization led by Dr. Ge Li, the company’s Founder and Chairman, and backed by AllyBridge. WuXi is spinning off pieces of its CRO/CDMO empire, conducting IPOs for each, and already showing that the privatization will be very profitable for its investors.
Source: China Biotoday
